Application and practice of integrated diagnosis of glioma

doi:10.3969/j.issn.1672-6731.2019.12.003

Abstract

Abstract:

Since the publication of the 2016 WHO of Tumors of the Central Nervous System (hereinafter referred to as 2016 WHO), many pathologists face challenges and confusion in "integrated diagnosis" practices of 2016 WHO due to financial or technical problems. In this review, the authors combines their practice experiences and their understanding of "cIMPACT-NOW update 1-4", and they discuss the hot issues of "integrated diagnosis", including:how to diagnose astrocytoma and oligodendroglioma, how to diagnose glioma with H3 gene mutation, How to diagnose IDH wild-type/H3 wild-type glioma and how to diagnose pediatric glioma. It is hopeful for helping Chinese neuropathologists to have a better understanding of glioma diagnostic terminology.

Key words: Glioma, Pathology, molecular, Integrated diagnosis (Not in MeSH), Review

摘要：

自2016世界卫生组织中枢神经系统肿瘤分类第四版修订版推行整合诊断模式以来，囿于经济条件和技术水平的差异，胶质瘤的病理诊断仍存在各种困惑和挑战。通过结合自身临床体会，以及对中枢神经系统肿瘤分子信息与分类实践联盟（cIMPACT-NOW）更新1~4的理解，浅谈弥漫性星形细胞和少突胶质细胞起源肿瘤、H3突变型胶质瘤、IDH野生型/H3野生型星形细胞肿瘤及儿童胶质瘤的整合诊断实践和热点问题。

关键词: 神经胶质瘤, 病理学, 分子, 整合诊断(非MeSH词), 综述

LI Hai-nan, LI Zhi. Application and practice of integrated diagnosis of glioma[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2019, 19(12): 920-924.

李海南, 李智. 谈胶质瘤整合诊断实践与热点问题[J]. 中国现代神经疾病杂志, 2019, 19(12): 920-924.

/ / Recommend / Download Citations

URL: http://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2019.12.003

http://journal11.magtechjournal.com/cjcnn/EN/Y2019/V19/I12/920

References

[1] Louis DN. WHO classification and grading of tumors of the central nervous system[M]//Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of the tumors of the central nervous system. Lyon:IARC, 2016:12-13.
[2] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system:a summary[J]. Acta Neuropathologica, 2016, 131:803-820.
[3] Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M. cIMPACT-NOW update 1:not otherwise specified(NOS) and not elsewhere classified (NEC)[J]. Acta Neuropathol, 2018, 135:481-484.
[4] Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P. cIMPACT-NOW update 2:diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant[J]. Acta Neuropathol, 2018, 135:639-642.
[5] Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients[J]. Cancer Sci, 2012, 103:587-592.
[6] Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K.Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss[J]. ActaNeuropathol, 2013, 126:267-276.
[7] Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA Network. IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas[J]. Neuro Oncol, 2018, 20:716-718.
[8] Hochart A, Escande F, Rocourt N, Grill J, Koubi-Pick V, Beaujot J, Meignan S, Vinchon M, Maurage CA, Leblond P. Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma[J].Ann Clin Transl Neurol, 2015, 2:439-443.
[9] Li HN, Shan CG, Fan CZ, Cheng LN, Wu SG, Liu MT, Jiang GY, Li Z. Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation:an analysis of 30 cases[J]. Zhonghua Bing Li Xue Za Zhi, 2019, 48:192-198.[李海南, 山常国, 范冲竹, 成丽娜, 伍世刚, 刘敏婷, 蒋光愉, 李智.H3K27M突变型弥漫性中线胶质瘤30例临床病理学特征和预后分析[J]. 中华病理学杂志, 2019, 48:192-198.]
[10] Kleinschmidt-Demasters BK, Mulcahy Levy JM. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis[J]. Clin Neuropathol, 2018, 37:53-63.
[11] Pratt D, Natarajan SK, Banda A, Gliannini C, Vats P, Koschmann C, Mody R, Chinnaiyan A, Venneti S. Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas[J].Acta Neuropathol, 2018, 135:299-301.
[12] Rodriguez FJ, Brosnan-Cashman JA, Allen SJ, Vizcaino MA, Giannini C, Camelo-Piragua S, Webb M, Matsushita M, Wadhwani N, Tabbarah A, Hamideh D, Jiang L, Chen L, Arvanitis LD, Alnajar HH, Barber JR, Rodriguez-Velasco A, Orr B, Heaphy CM.Alternative lengthening of telomeres, ATRX loss and h3-k27m mutations in histologically defined pilocytic astrocytoma with anaplasia[J]. Brain Pathol, 2019, 29:126-140.
[13] von Bueren AO, Karremann M, Gielen GH, Benesch M, Fouladi M, van Vuurden DG, van Zanten SEMV, Hoffman LM, Kramm CM. A suggestion to introduce the diagnosis of "diffuse midline glioma of the pons, H3 K27 wildtype (WHO grade Ⅳ)"[J]. Acta Neuropathol, 2018, 136:171-173.
[14] Castel D, Philippe C, Kergrohen T, Sill M, Merlevede J, Barret E, Puget S, Sainte-Rose C, Kramm CM, Jones C, Varlet P, Pfister SM, Grill J, Jones DTW, Debily MA. Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location[J]. Acta Neuropathol Commun, 2018, 6:117.
[15] Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Frühwald MC, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, JabadoN. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatricglioblastoma[J]. Nature, 2012, 482:226-231.
[16] Korshunov A, Capper D, Reuss D, Schrimpf D, Ryzhova M, Hovestadt V, Sturm D, Meyer J, Jones C, Zheludkova O, Kumirova E, Golanov A, Kool M, Schüller U, Mittelbronn M, Hasselblatt M, Schittenhelm J, Reifenberger G, Herold-Mende C, Lichter P, von Deimling A, Pfister SM, Jones DT. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity[J]. Acta Neuropathol, 2016, 131:137-146.
[17] Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, Perry A, Lichter P, von Deimling A, Pfister SM, Jones DT. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers[J].Acta Neuropathologica, 2015, 129:669-678.
[18] Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M. cIMPACT-NOW update 3:recommended diagnostic criteria for "diffuse astrocyticglioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade Ⅳ"[J]. Acta Neuropathol, 2018, 138:805-810.
[19] Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, Reifenberger G, Weller M, Hänggi D, Wick W, Herold-Mende C, Westphal M, Brandner S, Pfister SM, Capper D, Sahm F, von Deimling A. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma[J]. Acta Neuropathol, 2018, 136:793-803.
[20] Minju L, Young KS, Yeon-Lim S. Genetic alterations of epidermal growth factor receptor in glioblastoma:the usefulness of immunohistochemistry[J]. Appl Immunohist Molec Morphol, 2019, 27:589-598.
[21] Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN, Kros JM, Dirven CMF, Vincent AJPE, van den Bent MJ. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas:assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification[J]. Acta Neuropathol, 2017, 134:957-959.
[22] Smits A, Jakola AS. Clinical presentation, natural history, and prognosis of diffuse low-grade gliomas[J]. Neurosurg Clin NAM, 2019, 30:35-42.
[23] Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, Tang B, Haupfear K, Punchihewa C, Easton J, Mulder H, Boggs K, Shao Y, Rusch M, Becksfort J, Gupta P, Wang S, Lee RP, Brat D, Peter Collins V, Dahiya S, George D, Konomos W, Kurian KM, McFadden K, Serafini LN, Nickols H, Perry A, Shurtleff S, Gajjar A, Boop FA, Klimo PD Jr, Mardis ER, Wilson RK, Baker SJ, Zhang J, Wu G, Downing JR, Tatevossian RG, Ellison DW. Genetic alterations in uncommon low-grade neuroepithelial tumors:BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology[J]. Acta Neuropathol, 2016, 131:833-845.
[24] Ellison DW, Hawkins C, Jones DTW, Onar-Thomas A, Pfister SM, Reifenberger G, Louis DN. cIMPACT-NOW update 4:diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF V600E mutation[J]. Acta Neuropathol, 2019, 137:683-687.

Please choose a citation manager

Content to export